Antiretroviral therapy coverage among people living with HIV in key populations (A–E)

Export Indicator

Percentage of the people living with HIV in a key population receiving antiretroviral therapy in the past 12 months
What it measures

Progress towards providing antiretroviral therapy to people living with HIV in key populations.

This indicator is divided into five subindicators:

A. Antiretroviral therapy coverage among sex workers living with HIV

B. Antiretroviral therapy coverage among gay men and other men who have sex with men living with HIV

C. Antiretroviral therapy coverage among people who inject drugs living with HIV

D. Antiretroviral therapy coverage among transgender people living with HIV

E. Antiretroviral therapy coverage among people in prisons and other closed settings living with HIV

Rationale
Antiretroviral therapy has been shown to reduce HIV-related morbidity and mortality among people living with HIV and to reduce the transmission of HIV. People living with HIV in key populations should be able to access mainstream services that provide antiretroviral therapy without fear of facing stigma or discrimination and to be able to receive care from health-care workers who have the clinical knowledge to meet their specific needs. Ideally, all of these mainstream services should meet the standards for becoming sensitized to the needs of key populations. Accordingly, antiretroviral therapy coverage is a crucial way of assessing access to mainstream services.
Numerator

Number of respondents living with HIV who report receiving antiretroviral therapy in the past 12 months

Denominator

Number of respondents living with HIV

Calculation

Numerator/denominator

Method of measurement

Behavioural surveillance or other special surveys.

Measurement frequency

Every two years for behavioural surveys

Annual if special programme data are available

Disaggregation
A, C, and E: Gender (female, male and transgender)
 
D: Gender (transman, transwoman, other)
 
A-E: Age (<25 and 25+ years)
Additional information requested

If there are subnational data available, please provide the disaggregation by administrative area, city, or site in the space provided. Submit the digital version of any available survey reports using the upload tool.

Strengths and weaknesses

This is a new indicator that recognizes the importance of antiretroviral therapy and the need to achieve equity in access to ART. This has not been a standard question in biobehavioural surveys. It is, however, increasingly asked in surveys, including household surveys. Treatment programmes do not collect data on risk behaviour and therefore do not comprise a routine source for this information. Data on treatment distribution permit measurement of the second 95 of the 95–95–95 target and provide information to advocate for equity for treatment access for all key population communities.

It remains unclear how many people will respond accurately to this question in a survey. Additional analysis and research is required to assess the validity of the responses and to improve the elicitation of valid responses in the future.

Further information

WHO, CDC, UNAIDS, FHI 360. Biobehavioral survey guidelines for Populations at Risk for HIV. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/bitstream/handle/10665/258924/9789241513012-en...).

Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key populations: supplement to the 2014 consolidated guidelines for HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/bitstream/handle/10665/177992/9789241508995_en...).

Related Indicators

AV.1 PLHIV on ART, 2020, WHO Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management (https://www.who.int/publications/i/item/consolidated-hiv-strategic-information-guidelines).